Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289351 · ClinicalTrials.gov registry record · Phase 4
Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis
A Phase 4 study, sponsored by Phoenix Children's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 162
- Enrollment target
NCT03289351: Completed Phase 4 study, sponsored by Phoenix Children's Hospital.
NCT03289351 is a Phase 4 study that has completed, run by Phoenix Children's Hospital. The registered enrollment target is 162 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03289351, a Phase 4 study, has completed, sponsored by Phoenix Children's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 162 participants
- Enrollment target
Study Summary
After appendix has been removed for perforated appendicitis, patients will receive postoperative antibiotics. In the last 5 years, the literature has transitioned from a 3 -drug therapy to 2-drug therapy. Now there is a recent literature suggesting a single-drug therapy may be safe and adequate. In fact, using zosyn (piperacillin-tazobactam) as a single-drug therapy, there are additional benefits of simplicity, compliance, and lower infectious complications. Currently surgeons are already using both 2-drug regimen (ceftriaxone/metronidazole) and single-drug regimen (zosyn) interchangeable as both are FDA approved and regulated antibiotics for intra-abdominal infection. There is a clear need to compare outcomes between these two options.
Primary Outcome
Intra-abdominal abscess documented by ultrasound or computerized tomography
Interventions
- DRUG Piperacillin, Tazobactam Drug Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2017-05-22 |
| Est. Completion | 2023-11-07 |
| Phase | Phase 4 |
What the finished NCT03289351 record still lists
NCT03289351 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 1 intervention - of which Piperacillin, Tazobactam Drug Combination is the first listed.
NCT03289351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03289351 about?
NCT03289351 is a clinical study titled "Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis". After appendix has been removed for perforated appendicitis, patients will receive postoperative antibiotics. In the last 5 years, the literature has transitioned from a 3 -drug therapy to 2-drug therapy. Now there is a recent literature suggesting a single-drug therapy may be safe and adequate. In ...
What is the current status of trial NCT03289351?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 162 participants. The study started on 2017-05-22. Estimated completion is 2023-11-07.
What interventions are being tested in trial NCT03289351?
The interventions under investigation include: Piperacillin, Tazobactam Drug Combination (DRUG).
Who is sponsoring clinical trial NCT03289351?
This trial is sponsored by Phoenix Children's Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03289351's enrollment target sits among peer trials
162 503rd of 2000 higher than 1,495 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI